326 related articles for article (PubMed ID: 30842242)
61. ISA101 and nivolumab for HPV-16
Sousa LG; Rajapakshe K; Rodriguez Canales J; Chin RL; Feng L; Wang Q; Barrese TZ; Massarelli E; William W; Johnson FM; Ferrarotto R; Wistuba I; Coarfa C; Lee J; Wang J; Melief CJM; Curran MA; Glisson BS
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193933
[TBL] [Abstract][Full Text] [Related]
62. Juvenile-onset recurrent respiratory papillomatosis.
Maturo SC; Hartnick CJ
Adv Otorhinolaryngol; 2012; 73():105-8. PubMed ID: 22472239
[TBL] [Abstract][Full Text] [Related]
63. Juvenile onset recurrent respiratory papillomatosis: possibilities for successful antiviral therapy.
Kimberlin DW; Malis DJ
Antiviral Res; 2000 Feb; 45(2):83-93. PubMed ID: 10809017
[TBL] [Abstract][Full Text] [Related]
64. Solitary squamous cell papilloma of the lung in a 40-year-old woman with recurrent laryngeal papillomatosis.
Harada H; Miura K; Tsutsui Y; Mineta H; Urano M; Abe M; Kuroda M; Kasahara M
Pathol Int; 2000 May; 50(5):431-9. PubMed ID: 10849335
[TBL] [Abstract][Full Text] [Related]
65. Treatment outcomes of recurrent respiratory papillomatosis : Retrospective analysis of juvenile and adult cases.
Papaioannou VA; Lux A; Voigt-Zimmermann S; Arens C
HNO; 2018 Jan; 66(Suppl 1):7-15. PubMed ID: 28840259
[TBL] [Abstract][Full Text] [Related]
66. Laryngopharyngeal reflux and herpes simplex virus type 2 are possible risk factors for adult-onset recurrent respiratory papillomatosis (prospective case-control study).
Formánek M; Jančatová D; Komínek P; Matoušek P; Zeleník K
Clin Otolaryngol; 2017 Jun; 42(3):597-601. PubMed ID: 27759910
[TBL] [Abstract][Full Text] [Related]
67. Clinical course of recurrent respiratory papillomatosis: comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11.
Tjon Pian Gi RE; San Giorgi MR; Slagter-Menkema L; van Hemel BM; van der Laan BF; van den Heuvel ER; Dikkers FG; Schuuring EM
Head Neck; 2015 Nov; 37(11):1625-32. PubMed ID: 24955561
[TBL] [Abstract][Full Text] [Related]
68. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
[TBL] [Abstract][Full Text] [Related]
69. Quantification and Functional Studies of Neutrophilic Cells Identifies Distinct Papilloma Phenotypes.
Bai K; Clavijo PE; Robbins Y; Norberg SM; Allen CT
Laryngoscope; 2024 Jul; 134(7):3238-3244. PubMed ID: 38436434
[TBL] [Abstract][Full Text] [Related]
70. Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement.
So RJ; Hidalgo Lopez JC; Ballestas SA; Klein AM; Steuer C; Shin DM; Abousaud M; Teng Y; Saba NF; Tkaczuk AT; Schaefer ES; Seiwert TY; McClellan K; Best SR
Laryngoscope; 2024 Feb; 134(2):577-581. PubMed ID: 37470254
[TBL] [Abstract][Full Text] [Related]
71. Preliminary report of endolaryngeal and endotracheal laser surgery of juvenile-onset recurrent respiratory papillomatosis by Nd:YAG laser and a new fiber guidance instrument.
Janda P; Leunig A; Sroka R; Betz CS; Rasp G
Otolaryngol Head Neck Surg; 2004 Jul; 131(1):44-9. PubMed ID: 15243556
[TBL] [Abstract][Full Text] [Related]
72. The predictive value of serum interleukins in recurrent respiratory papillomatosis: a preliminary study.
Snowden RT; Thompson J; Horwitz E; Stocks RM
Laryngoscope; 2001 Mar; 111(3):404-8. PubMed ID: 11224768
[TBL] [Abstract][Full Text] [Related]
73. Detection of human papillomavirus infection in diseased and nondiseased sites of the respiratory tract in recurrent respiratory papillomatosis patients by DNA hybridization.
Pignatari S; Smith EM; Gray SD; Shive C; Turek LP
Ann Otol Rhinol Laryngol; 1992 May; 101(5):408-12. PubMed ID: 1315130
[TBL] [Abstract][Full Text] [Related]
74. Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey.
Best SR; Mohr M; Zur KB
Laryngoscope; 2017 Oct; 127(10):2225-2229. PubMed ID: 28657692
[TBL] [Abstract][Full Text] [Related]
75. Harnessing the PD-1 Pathway in Myelodysplastic Syndrome.
Mukherjee S; Ibrahimi S; Aljumaily R; Cherry M
Am J Ther; 2018; 25(6):e711-e712. PubMed ID: 29394170
[No Abstract] [Full Text] [Related]
76. Economic impact of recurrent respiratory papillomas in a UK adult population.
Harrison A; Montgomery J; Macgregor FB
J Laryngol Otol; 2016 Jul; 130(7):645-9. PubMed ID: 27188701
[TBL] [Abstract][Full Text] [Related]
77. Respiratory Papillomatosis.
Dentale N; Trisolini R
N Engl J Med; 2019 Jul; 381(4):358. PubMed ID: 31340095
[No Abstract] [Full Text] [Related]
78. Management of two cases of tracheobronchial management of two cases of tracheobronchial papillomatosis at tertiary hospital in Indonesia: A case report.
Perdana RF
Int J Surg Case Rep; 2021 Jun; 83():106054. PubMed ID: 34090191
[TBL] [Abstract][Full Text] [Related]
79. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53.
Rady PL; Schnadig VJ; Weiss RL; Hughes TK; Tyring SK
Laryngoscope; 1998 May; 108(5):735-40. PubMed ID: 9591556
[TBL] [Abstract][Full Text] [Related]
80. The role of HPV11 E7 in modulating STING-dependent interferon β response in recurrent respiratory papillomatosis.
Chen L; Hu H; Pan Y; Lu Y; Zhao M; Zhao Y; Wang L; Liu K; Yu Z
J Virol; 2024 May; 98(5):e0192523. PubMed ID: 38624230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
